Seres Therapeutics, which is developing therapies that replace beneficial bacteria to treat infections, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Formerly known as Seres Health, the biotech is first targeting Clostridium difficile infection (CDI). March 2015 US IPO Summit Therapeutics (SMMT; +9%) also targets CDI, and May 2015 IPO OpGen (OPGN; -39%) is developing genetic tests that identify multi-drug resistant infections like CDI.
The Cambridge, MA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol MCRB. Seres Therapeutics initially filed confidentially on December 11, 2014. Goldman Sachs and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
